Anthrax Vaccine Adsorbed Emergent BioSolutions Articles
PharmAthene gets additional $78.4 million under existing SparVax anthrax vaccine contract with HHS
24 February 2010
Emergent Bio's BioThrax OKed in India
16 February 2009
Shorter schedule approved for Emergent's BioThrax in USA
12 January 2009
Up to $448M US govt BioThrax contract
6 October 2008
Emergent gets HHS nod for Anthrax vacc contract
22 September 2008
Emergent Bio in anthrax vacc deal
12 May 2008
US government "wasting $100M" on anthrax drugs
29 October 2007
$448M HHS contract for Emergent Bio
8 October 2007
November a lackluster month for biotechnology stocks, says Burrill
18 December 2006
DOR plans deal with UK Ministry of Defence
20 January 2003
Showing 1-11 of 11 articles
- 1
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
